Asensus Surgical (ASXC) Stock Price
Asensus Surgical Price
Revenue has compounded at 64.9% per year over the past 11 years to 8.58 M USD. Asensus Surgical's net margin stands at -914.5%, up from -1,807.5% several years earlier. Analysts set a median price target of 0.36 USD, implying 2.6% above the current price. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus.
Asensus Surgical stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Asensus Surgical business model & stock analysis
Frequently asked questions about Asensus Surgical
Asensus Surgical Inc's business model revolves around developing and commercializing advanced surgical technologies. The company's focus lies in revolutionizing minimally invasive surgery through its innovative platform, the Senhance Surgical System. This system relies on machine vision algorithms and robotic technology to provide surgeons with enhanced precision, control, and automation. By offering advanced surgical tools and technologies, Asensus Surgical Inc aims to improve patient outcomes, reduce healthcare costs, and advance the field of surgery. Asensus Surgical Inc continues to drive innovation and collaboration in the healthcare industry, positioning itself as a leader in the field of surgical robotics.
Asensus Surgical Inc, a leading medical device company, operates primarily in the healthcare industry. With its innovative surgical robotic systems, including the Senhance Surgical System, Asensus Surgical is focused on transforming minimally invasive surgery by enhancing patient outcomes and surgeon capabilities. The company's advanced technologies and platforms empower healthcare professionals across various specialties, such as general surgery, gynecology, urology, and thoracic surgery. By leveraging artificial intelligence and machine learning, Asensus Surgical aims to improve surgical precision and ultimately redefine the future of surgery.
The main competitors of Asensus Surgical Inc in the market are Intuitive Surgical Inc, Medtronic PLC, and Johnson & Johnson.
Asensus Surgical Inc, formerly known as TransEnterix, is a medical device company headquartered in Research Triangle Park, North Carolina. It focuses on digitizing the interface between the surgeon and patient by utilizing the latest robotic-assisted surgical technologies. The company's flagship product, Senhance Surgical System, combines advanced robotics with innovative instrumentation to enhance the minimally invasive surgery experience. Asensus Surgical Inc has a rich history of pioneering groundbreaking surgical technologies and continues to revolutionize surgical outcomes. With a strong commitment to innovation and patient care, the company strives to improve surgical precision, reduce variability, and enable better clinical outcomes for patients worldwide.
Asensus Surgical Inc has achieved several significant milestones. The company successfully received FDA clearance for their flagship product, the Senhance Surgical System, which revolutionizes minimally invasive surgery through robotic technology. Asensus Surgical Inc has also secured strategic partnerships and collaborations with renowned healthcare institutions and industry leaders. The company's dedication to innovation is evident through their continuous research and development efforts, as well as their commitment to providing surgeons with state-of-the-art surgical solutions. Asensus Surgical Inc strives to improve patient outcomes and enhance surgical capabilities globally, solidifying its position as a leader in robotic surgical platforms.
Asensus Surgical Inc is primarily present in the United States.
Asensus Surgical Inc represents values of innovation, precision, and patient-centricity. The company's corporate philosophy is focused on revolutionizing surgical procedures through robotics and digital technologies. Asensus Surgical Inc aims to provide surgeons with enhanced control, efficiency, and outcomes, ultimately improving patient care. With a commitment to advancing minimally invasive surgery, Asensus Surgical Inc embraces a culture of collaboration, continuous learning, and excellence. Pioneering the future of surgical robotics, the company combines cutting-edge technologies with a dedication to transforming the way surgeries are performed. Asensus Surgical Inc's vision revolves around empowering surgeons and healthcare providers with advanced tools to deliver safer, more effective, and more personalized surgical experiences.
Analysts currently set an average price target of 0.36 USD for the Asensus Surgical stock (median: 0.36 USD), implying +2.6 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Asensus Surgical stock: 0 recommend buying, 4 holding and 3 selling. For 2026, analysts expect Asensus Surgical to generate revenue of 51.38 M USD and earnings per share of -0.09 USD.
Converted at the current exchange rate, the Asensus Surgical share trades at 0.31 EUR (0.35 USD).
The Asensus Surgical share (ASXC) is listed on 4 stock exchanges, including: Frankfurt (2TX.F), München (2TX.MU), Düsseldorf (2TX.DU).
Asensus Surgical, Inc. is a leading provider of robotic systems and digital solutions for surgical procedures. The company focuses on developing, manufacturing, and marketing innovative products that ensure higher accuracy, efficiency, and safety in surgery.
The expected revenue of Asensus Surgical is 51.38 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Asensus Surgical is -21.83 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Asensus Surgical is currently -3.98. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Asensus Surgical stock.
The price-to-sales ratio (P/S) of Asensus Surgical is currently 1.69. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Asensus Surgical stock.
The Eulerpool Quality Score for Asensus Surgical is 4/10.
The ISIN of Asensus Surgical is US04367G1031. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Asensus Surgical is A2PW06. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Asensus Surgical is ASXC. The ticker symbol is used to trade Asensus Surgical shares on the stock exchange.
Asensus Surgical stock
Asensus Surgical Peer Group
Asensus Surgical Ticker
Asensus Surgical FIGI
All fundamentals and in-depth analysis of Asensus Surgical
Our stock analysis for Asensus Surgical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Asensus Surgical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.